Pipeline researchers have developed an ultimate drug for malaria using the synthesis of the next generation (AI).
Malaria is one of the world's biggest infectious diseases, according to research published in the scientific journal Journal Journal.
Plasmodium falciparum, the most dangerous human parasite, is believed to cause hundreds of millions of diseases. An estimated 1 million deaths will die in a year, according to Insulio Meditation Taiwan.
Plasmodium falciparum produces malaria by causing haloglobin in humans. This is done by Fascin-2 (FP2).
The researchers suggest that FP2 block hemoglobin destruction and parabetet development are a good aim for the FP2 inhalibil antibiotrial therapy.
Drugs that are controlled by malaria can increase the immune system.
New antimicrobial drugs are needed urgently to combat new targets.
In order to cope with this challenge, researchers in Taiwan have been widely studied by the proteins analyzer in the E64 approach, interacting with them and blocking FP2.
E64's efficiency and functionalities and the likelihood of derivatives in E64 Helps E64 and its derivatives to treat patients with high levels of systin proteins primarily due to prevalence of low intensity in humans.
The findings show that the condition of EPP and FP2 is supported by FP2's earlier binding pocket and FP2's amino acids.
The antimilial drug design not only detects the use of drugs, but also connects with the remains of the established bending pocket, the presence of drug users, and the ruins of the established binding pocket subtis.
"Taiwan is ready to work on malaria activities that will save millions of lives," said CEO of Intiliac Meditation Taiwan.
The results confirm that E64 can forbid FP2, and describes the physical structure of the E64's interaction with FP2 in a very positive way.